Monte Rosa Therapeutics, Inc.
GLUE · XNASCIK 1826457fmd_019QK044RGEV7K1HQDGZ4NGM6WManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 76 | 124 |
| Research and development | 24 | 57 | 85 | 111 | 122 | 142 |
| Total operating expenses | 28 | 73 | 112 | 143 | 157 | 178 |
| Compensation and benefits | – | – | – | 20 | 22 | – |
| Operating income | (28) | (73) | (112) | (143) | (81) | (54) |
| Other non-operating income (expense) | (8) | (1) | 4 | 8 | 11 | 14 |
| Income before taxes | (36) | (74) | (109) | (135) | (70) | (40) |
| Income tax expense | – | – | 0 | 0 | 3 | (1) |
| Net income from continuing operations | – | – | (109) | (135) | (73) | (39) |
| Net income | (36) | (74) | (109) | (135) | (73) | (39) |